Oros Research Peptides Scam? 🚩
- Wildcat Commerce
- Nov 17
- 7 min read
COMPLETE SCAM WATCHING REPORT |
Company Details: Oros Research
Entity: OROS Research / OROS, Inc.
BBB Officers Listed:
Zack Joseph, Vice President / Co-Founder
Tommy Guess, President / Co-Founder
Claimed Address: 105 Brady Ct. #B, Cary, NC 27511
Phone: +1 (910) 250-8786
Claimed Manufacturing Facility: “Formulated in our California-based partner facility under strict GMP-compliant conditions.”
Legal Entity Listed in Terms: OROS, Inc.
Business Start Date (According to BBB): March 12, 2025
Incorporation Date: March 12, 2025
Alternate Names / DBA: “OROS, Inc.”
Employed (LinkedIn): 2-10 listed
Social Media:
Facebook page: titled “OROS Research” https://www.facebook.com/orosresearch
Instagram: @orosresearch https://www.instagram.com/orosresearch
X: @orosresearch https://x.com/orosresearch
Scam Score
A 1-star rating represents the lowest tier in our trust scale and signals high probability of deception, non-compliance, or consumer harm. Vendors in this category exhibit one or more of the following:
Verified false or misleading claims about origin, purity, or manufacturing.
Unverifiable lab documents (missing accreditation, self-issued, or forged).
Violations of federal or platform policies (FDA, FTC, Shopify, Stripe, etc.).
Mismatch between corporate filings, claimed experience, and public data.
Evidence of dosing/reconstitution instructions implying human use despite “research only” disclaimers.
Impact:
This low of a trust score automatically places the entity on ScamWatching.org red-flag status 🚩— meaning the brand is considered untrustworthy until independently verified. Listings under this score are recommended for public exposure, platform reporting, and community alerting.
OROS RESEARCH GENERAL OVERIVIEW
Oros Research presents itself as a U.S.-based manufacturer of “high-purity, California-made” research peptides through its website at https://orosresearch.com. According to the Better Business Bureau listing for the company (https://www.bbb.org/us/nc/cary/profile/biotechnology/oros-research-0593-90366833), Oros Research was incorporated on March 12, 2025, making it an extremely new operation despite its polished pharmaceutical-style branding. Domain registration records from ScamAdviser (https://www.scamadviser.com/check-website/orosresearch.com) show that the site itself was registered just weeks before incorporation, raising immediate concerns about how a newly formed business can claim established GMP facilities and DEA-licensed laboratory partnerships.
SUMMARY ASSESSMENT
Oros Research operates through its website, https://orosresearch.com, and lists its corporate identity as OROS, Inc. According to the Better Business Bureau, the company was founded and incorporated on March 12, 2025, making it a very new entrant into the peptide market. The BBB listing identifies two individuals as company officers: Zack Joseph, serving as Vice President and Co-Founder, and Tommy Guess, listed as President and Co-Founder. Oros Research claims to be headquartered at 105 Brady Ct. #B, Cary, North Carolina, which serves as its primary business address. The company provides a single contact number, +1 (910) 250-8786, and maintains a social media presence through a Facebook page under the name “Oros Research.”
On its website, Oros Research describes itself as a distributor of research-use-only (RUO) peptides, emphasizing that its products are “not intended for human or animal consumption.” However, despite this RUO positioning, the company markets its peptides with pharmaceutical-style branding, complete with lot numbers, endotoxin testing claims, and references to sterile formulation environments.
What Oros Research Claims
Across its website, Oros Research repeatedly asserts that its peptides are “California-Made” and manufactured in a “California-based partner facility under strict GMP and ISO-compliant conditions.” These statements appear prominently on the homepage (https://orosresearch.com) and again in the company FAQ (https://orosresearch.com/pages/faq). The legal disclaimers reinforce that all products are tested at “DEA-licensed, U.S.-based laboratories.”
However, no page on the site provides a facility name, address, license number, GMP certificate, ISO credential, or DEA laboratory identifier. The company continues to operate exclusively from its North Carolina address, with no public record of a corresponding California manufacturing plant in the California Secretary of State business registry (https://bizfileonline.sos.ca.gov/search/business).
If Oros Research truly manufactures its peptides in California, why is the only verifiable business address located in North Carolina, with no evidence of any California facility? Even the laboratory they claim performs their COA testing is not based in California, further undermining their manufacturing claims.
This photo shows the business address listed on Oros Research’s own website. As the screenshot confirms, there is no indication of any California-based manufacturing facility at this location, further undermining their claim of operating a “California lab.”
VIOLATIONS AND RED FLAGS
Discrepancies in Manufacturing Claims
Although the company makes repeated claims about California manufacturing, no public filing exists for OROS, Inc. or Oros Research in the state of California — and no manufacturing site is disclosed anywhere on the website. The only verified physical location remains the Cary, North Carolina office listed on both the Contact Page and the BBB record.
This mismatch between claimed and verifiable facility locations is significant. Given that Oros Research was incorporated on March 12, 2025 (BBB), and its website registered on February 18, 2025 (ScamAdviser), it is unlikely that the company established a fully compliant GMP manufacturing plant in California during this timeframe. No FDA manufacturing registration or outsourcing facility listing exists for Oros Research in the FDA 503B Outsourcing Facility Database (https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities).
Product Presentation That Mirrors Consumer-Use Peptide Vendors
Despite labeling its products as RUO, Oros Research markets sterile peptide vials in exact consumer-ready dosing formats, including 5mg, 10mg, and 15mg sterile lyophilized powders. Examples include Retatrutide (https://orosresearch.com/products/retatrutide-peptide),
Melanotan-II (https://orosresearch.com/products/melanotan-2),and GHK-Cu/BPC-157/TB-500 “Glow Blend” (https://orosresearch.com/products/ghk-cu-bpc157-tb500).
They also sell BPC-157 capsules (https://orosresearch.com/products/bpc-157-capsules), a dosage form intended for oral consumption — not laboratory research.
FDA has publicly warned against peptide suppliers using RUO language to disguise products clearly intended for human use. See FDA’s RUO Guidance (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/research-use-only-ruo-labeling-medical-devices) and FDA’s consumer update on unapproved peptides (https://www.fda.gov/consumers/consumer-updates/avoid-unapproved-hormones-and-peptides). These warnings directly apply to the types of products Oros Research is selling.
Inconsistent Use of Regulatory Terminology
Oros Research states that RUO products are “not subject to serialization requirements” (Terms & Conditions), yet the company simultaneously displays lot numbers and purity percentages on product pages, creating conflicting messaging. Claims of “GMP” and “ISO 5 Laminar Flow Facility” appear in multiple sections of the site, but unlike legitimate manufacturers, the company provides no facility certification numbers, no ISO reports, no audit documentation, and no GMP site listing.
FDA guidance on misbranding (https://www.fda.gov/industry/fda-basics-industry/drug-misbranding) highlights that using regulatory language without lawful compliance is considered misleading — another area where Oros Research’s claims appear problematic.
The COA Lab: Freedom Diagnostics Testing
Oros Research states that its COAs come from “DEA-licensed” labs, but multiple product pages and support notes reference Freedom Diagnostics Testing, whose website is https://freedomdiagnosticstesting.com.
Freedom Diagnostics Testing lists an address at 133 Holiday Ct Suite 106, Franklin, TN 37067
This same suite, however, is used by multiple unrelated businesses, including Farmers Insurance – Kevin Clingan (https://agents.farmers.com/tn/franklin/kevin-clingan) and Employee Prosperity Partners . There is no indication that a licensed analytical laboratory operates at this location.
The Freedom Diagnostics blog shows only a default “Hello world!” post dated February 14, 2025, confirming the site was created just days before Oros Research’s own domain registration. Domain verification (ScamAdviser) for Freedom Diagnostics also confirms February 2025 creation: https://www.scamadviser.com/check-website/freedomdiagnosticstesting.com
Critically, no CLIA license, ISO 17025 accreditation, state lab license, or DEA analytical lab listing exists for Freedom Diagnostics Testing in the NPI Registry (https://npiregistry.cms.hhs.gov/search) or the DEA analytical laboratory directory (https://www.deadiversion.usdoj.gov).
This suggests the lab may not exist as a legitimate analytical facility and may instead be a companion entity created to give Oros Research the appearance of third-party testing.
A Reddit discussion on peptide testing labs (https://www.reddit.com/r/massspectrometry/comments/14fjda1/need_recommendation_on_who_can_test_peptides_for/) also raises concerns about suspicious and unverifiable labs being used by emerging peptide vendors.
To back up on U/dDhyana response, we believe we have found some of Freedom Diagnostics "shill" accounts created to advertise them on reddit.
Coordinated Website Creation Timeline
A striking detail in this investigation is the timing of the domain registrations. OROS Research (orosresearch.com) was registered on February 18, 2025, and the testing lab they claim to use, Freedom Diagnostics Testing
(freedomdiagnosticstesting.com), was registered just four days earlier on February 14, 2025.
The close timing suggests both entities emerged simultaneously, raising serious questions about whether the “independent third-party testing lab” existed before OROS Research needed it. Rather than two established companies partnering, the evidence points toward two newly created websites built in parallel — a pattern that often appears in manufactured legitimacy or self-issued COA ecosystems.
FDA Crackdown: Three Peptide Companies Cited for the Same Violations Seen at Alpha BioMed
These are not isolated cases. Recent FDA warning letters to GLP-1 Solution, ASN-LABS, and SemaSpace all describe the same core violations: online vendors selling Semaglutide, Tirzepatide, Retatrutide and related GLP-1 drugs directly to consumers as “research” or “compounded” products, without approval and with misleading marketing.
Oros Research’s catalog of GLP-1-style peptides, cosmetic “blend” formulations, and research-only disclaimers places it squarely inside this enforcement pattern, even if it has not (yet) appeared on the FDA’s warning-letter list.
Here are the top 3 companies that has been cited for the same violations seen at Oros Research
GLP-1 Solution (glp1solution.store) | WARNING LETTER (Sept 9, 2025) Direct link to warning letter: U.S Food & Drug Administration | Despite claiming to offer “compounded” GLP-1 products, the company marketed retatrutide, semaglutide, and tirzepatide as consumer-ready drugs. FDA determined they were unapproved new drugs and misbranded, violating 505(a), 502(f)(1), 301(a), and 301(d) of the FD&C Act. |
ASN-LABS (asn-labs.com) | WARNING LETTER (Sept 9, 2025) Direct link to warning letter: U.S Food & Drug Administration | FDA found the company was offering retatrutide and semaglutide online as drug alternatives despite lacking approvals. Products were ruled unapproved new drugs and misbranded, with marketing suggesting clinical/weight-loss use under the guise of “research chemicals.” |
SemaSpace (www.semaspace.com) | WARNING LETTER 665848 (Oct 2, 2023) Direct link to warning letter: U.S Food & Drug Administration | FDA determined SemaSpace was selling semaglutide injections directly to consumers. The company’s marketing implied human therapeutic use, despite no drug approval or FDA oversight. Violations included unapproved new drugs, misbranding, and unsafe interstate distribution. |
GLP-1 Solution Warning Letter Highlighting Their Violations:
ASN-LABS Warning Letter Highlighting Their Violations:
SemaSpace Warning Letter Highlighting Their Violations:
Public records, government databases, and the company’s own website collectively contradict Oros Research’s claims of California GMP manufacturing, DEA-licensed laboratory testing, and long-standing industry presence. The company appears to be a newly formed entity operating from a North Carolina office, selling peptides associated with human use despite RUO labeling, and relying on a testing lab that lacks recognizable licensing or laboratory credentials.
Both Oros Research and Freedom Diagnostics Testing show signs of being formed simultaneously, lacking transparency, and lacking the infrastructure expected of compliant peptide manufacturers and testing labs. These findings suggest consumers and researchers should exercise extreme caution and verify all claims independently before engaging with this vendor.
All findings and supporting evidence referenced in this report are sourced from publicly available records. Any attempt to alter or remove such material may constitute interference with public documentation and will be noted for compliance review.
______________________________________________________________________________________
Individuals who have experienced deceptive or unauthorized practices involving Alpha BioMed Labs are encouraged to file a report using our intake form for review and documentation. Submissions may be evaluated for potential escalation to a coordinated consumer complaint or class action proceeding if sufficient evidence is established.